Pardeep Nijhawan net worth and biography

Pardeep Nijhawan Biography and Net Worth

Founder of Exzell Pharma, Medical Futures, Inc., Edesa Biotech, Inc. (Old) and Digestive Health Clinic LLC, Pardeep Nijhawan presently occupies the position of Chief Executive Officer, Secretary & Director at Edesa Biotech, Inc.

He previously occupied the position of Chief Executive Officer & Director at Edesa Biotech, Inc. (Old) and Chief Executive Officer for Medical Futures, Inc.

He received a doctorate from the University of Ottawa.

What is Pardeep Nijhawan's net worth?: The estimated net worth of Pardeep Nijhawan is at least $1.48 million as of March 25th, 2024. Dr. Nijhawan owns 341,702 shares of Edesa Biotech stock worth more than $1,482,987 as of April 18th. This net worth estimate does not reflect any other investments that Dr. Nijhawan may own. Additionally, Dr. Nijhawan receives an annual salary of $475,330.00 as CEO at Edesa Biotech. Learn More about Pardeep Nijhawan's net worth.
How old is Pardeep Nijhawan?: Dr. Nijhawan is currently 53 years old. There are 1 older executives and no younger executives at Edesa Biotech. Learn More on Pardeep Nijhawan's age.
What is Pardeep Nijhawan's salary?: As the CEO of Edesa Biotech, Inc., Dr. Nijhawan earns $475,330.00 per year. Learn More on Pardeep Nijhawan's salary.
How do I contact Pardeep Nijhawan?: The corporate mailing address for Dr. Nijhawan and other Edesa Biotech executives is 100 SPY COURT, MARKHAM A6, L3R 5H6. Edesa Biotech can also be reached via phone at (289) 800-9600 and via email at [email protected]. Learn More on Pardeep Nijhawan's contact information.
Has Pardeep Nijhawan been buying or selling shares of Edesa Biotech?: Pardeep Nijhawan has not been actively trading shares of Edesa Biotech in the last ninety days. Most recently, on Monday, March 25th, Pardeep Nijhawan bought 5,000 shares of Edesa Biotech stock. The stock was acquired at an average cost of $4.00 per share, with a total value of $20,000.00. Following the completion of the transaction, the chief executive officer now directly owns 341,702 shares of the company's stock, valued at $1,366,808. Learn More on Pardeep Nijhawan's trading history.
Who are Edesa Biotech's active insiders?: Edesa Biotech's insider roster includes Michael Brooks (President), and Pardeep Nijhawan (CEO). Learn More on Edesa Biotech's active insiders.
Are insiders buying or selling shares of Edesa Biotech?: In the last year, Edesa Biotech insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $20,000.00. The most recent insider tranaction occured on March, 25th when CEO Pardeep Nijhawan bought 5,000 shares worth more than $20,000.00. Insiders at Edesa Biotech own 25.0% of the company. Learn More about insider trades at Edesa Biotech.
Information on this page was last updated on 3/25/2024.

Pardeep Nijhawan Insider Trading History at Edesa Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2024	Buy	5,000	$4.00	$20,000.00	341,702
6/30/2022	Buy	2,857	$11.20	$31,998.40	84,973
5/27/2022	Buy	714	$13.44	$9,596.16	82,116
5/24/2022	Buy	285	$12.60	$3,591.00	81,401
3/31/2022	Buy	285	$20.93	$5,965.05
3/29/2022	Buy	285	$21.14	$6,024.90
3/17/2022	Buy	285	$22.82	$6,503.70
3/15/2022	Buy	285	$19.60	$5,586.00
3/11/2022	Buy	1,000	$21.63	$21,630.00
3/9/2022	Buy	214	$21.35	$4,568.90
3/29/2021	Buy	285	$36.61	$10,433.85	78,187
3/24/2021	Buy	714	$36.12	$25,789.68	77,473
5/26/2020	Buy	428	$22.26	$9,527.28	76,758
3/17/2020	Buy	714	$13.09	$9,346.26	76,758

Pardeep Nijhawan Buying and Selling Activity at Edesa Biotech

Edesa Biotech Company Overview

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Today's Range

Now: $4.34

$4.34

$4.40

50 Day Range

MA: $4.64

$4.06

$5.67

2 Week Range

Now: $4.34

$2.46

$8.61

Volume

568 shs

Average Volume

8,516 shs

Market Capitalization

$13.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

Pardeep Nijhawan Biography and Net Worth

What is Pardeep Nijhawan's net worth?

How old is Pardeep Nijhawan?

What is Pardeep Nijhawan's salary?

How do I contact Pardeep Nijhawan?

Has Pardeep Nijhawan been buying or selling shares of Edesa Biotech?

Who are Edesa Biotech's active insiders?

Are insiders buying or selling shares of Edesa Biotech?